中欧悦享生活混合A（010336）成立日期2021年1月7日，最新规模20.04亿。今年以来收益11.47%，同 类排名5454/8138；近一年收益10.65%，同类排名5627/8055；成立以来亏损48.68%。 中欧悦享生活混合A（010336）基金经理为钱亚风云。 截至发稿，钱亚风云累计任职时间10年119天，现任基金资产总规模24.96亿元，任职期间最佳基金回报 242.9%， 任职期间最差基金回报-25.66%。 11月19日，毓恬冠佳跌5.01%，截至发稿，报46.46元/股，成交3887.95万元，换手率4.61%，总市值 40.81亿元。 资料显示，上海毓恬冠佳科技股份有限公司位于上海青浦工业园区崧煌路580号，成立日期2004年12月3 日，上市日期2025年3月3日，公司主营业务涉及公司是以汽车天窗为主要产品的汽车运动部件制造商, 拥有汽车天窗设计、研发、生产一体能力,主要服务于在中国设立的国内外知名汽车厂商以及部分海外 整车制造商,提供专业的、系统的各类汽车天窗以及其他汽车运动部件成套解决方案。主营业务收入构 成为：全景天窗65.29%，小天窗20.89%，其他13.82%。 从毓恬 ...

11月18日，海辰药业跌5.19%，截至发稿，报65.55元/股，成交3.97亿元，换手率7.14%，总市值78.66亿 元。 资料显示，南京海辰药业股份有限公司位于江苏省南京经济技术开发区恒发路1号，成立日期2003年1月 15日，上市日期2017年1月12日，公司主营业务涉及化学制剂、原料药及中间体的研发、生产、销售。 主营业务收入构成为：心脑血管类87.12%，抗生素类5.69%，原料药及中间体1.68%，消化类1.50%，抗 病毒类1.47%，其他(补充)0.83%，免疫调节类0.80%，其他类0.57%，利尿类0.34%。 从海辰药业十大流通股东角度 中欧悦享生活混合A（010336）基金经理为钱亚风云。 截至发稿，钱亚风云累计任职时间10年118天，现任基金资产总规模24.96亿元，任职期间最佳基金回报 242.9%， 任职期间最差基金回报-24.02%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，中欧基金旗下1只基金位居海 ...

11月12日，海辰药业跌5.22%，截至发稿，报54.10元/股，成交1.87亿元，换手率4.14%，总市值64.92亿 元。 中欧悦享生活混合A（010336）基金经理为钱亚风云。 截至发稿，钱亚风云累计任职时间10年112天，现任基金资产总规模24.96亿元，任职期间最佳基金回报 242.9%， 任职期间最差基金回报-26.19%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，南京海辰药业股份有限公司位于江苏省南京经济技术开发区恒发路1号，成立日期2003年1月 15日，上市日期2017年1月12日，公司主营业务涉及化学制剂、原料药及中间体的研发、生产、销售。 主营业务收入构成为：心脑血管类87.12%，抗生素类5.69%，原料药及中间体1.68%，消化类1.50%，抗 病毒类1.47%，其他(补充)0.83%，免疫调节类0.80%，其他类0.57%，利尿类0.34%。 从海辰药业十大流通股东角度 数据显示，中欧基金旗下1只基金位居海 ...

Group 1 - The core viewpoint of the news is that Haisun Pharmaceutical has seen a significant stock price increase, with a 5.07% rise on October 29, reaching 62.83 CNY per share, and a total market capitalization of 7.54 billion CNY [1] - Haisun Pharmaceutical's stock has increased for three consecutive days, with a cumulative increase of 15.62% during this period [1] - The company, established on January 15, 2003, specializes in the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] Group 2 - The main revenue composition of Haisun Pharmaceutical includes 87.12% from cardiovascular drugs, 5.69% from antibiotics, and smaller contributions from other categories such as digestive (1.50%) and antiviral (1.47%) drugs [1] - Among the top ten circulating shareholders, a fund under China Europe Fund, specifically the China Europe Enjoy Life Mixed A (010336), has entered the list, holding 937,000 shares, which is 1.14% of the circulating shares [2] - The fund has achieved a year-to-date return of 12.53% and a one-year return of 9.4%, ranking 5532 out of 8155 and 5727 out of 8031 in its category, respectively [2]

Group 1 - The core viewpoint of the news is that Yutian Guanjia (301173.SZ) has reported an increase in institutional holdings, indicating growing investor confidence in the company [1] - As of October 28, 2025, a total of 9 institutional investors hold shares in Yutian Guanjia, with a combined holding of 51.918 million shares, representing 59.11% of the total share capital [1] - Compared to the previous quarter, the total institutional holding percentage has increased by 0.33 percentage points [1] Group 2 - In the public fund sector, there was an increase in holdings from one public fund, specifically the China Europe Enjoy Life Mixed A fund, which saw an increase of 0.46% in its holdings [2] - A total of 1,976 public funds did not disclose their holdings in the current period, including funds such as Guojin Quantitative Multi-Factor A and Guojin Quantitative Selected A [2]

Group 1 - The core viewpoint of the news is that Hainan Pharmaceutical has seen a significant increase in its stock price, rising by 5.62% to reach 56.20 yuan per share, with a trading volume of 267 million yuan and a turnover rate of 5.89%, resulting in a total market capitalization of 6.744 billion yuan [1] - Hainan Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, is primarily engaged in the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The company's main business revenue composition includes cardiovascular drugs at 87.12%, antibiotics at 5.69%, active pharmaceutical ingredients and intermediates at 1.68%, digestive drugs at 1.50%, antiviral drugs at 1.47%, and other categories [1] Group 2 - Among the top circulating shareholders of Hainan Pharmaceutical, a fund under China Europe Fund has entered the top ten, specifically the China Europe Enjoy Life Mixed A Fund (010336), which holds 937,000 shares, accounting for 1.14% of the circulating shares [2] - The China Europe Enjoy Life Mixed A Fund was established on January 7, 2021, with a latest scale of 2.048 billion yuan, achieving a year-to-date return of 12.73% and a one-year return of 10.24% [2] - The fund manager, Qian Yafengyun, has a cumulative tenure of 10 years and 96 days, with the fund's total asset scale at 2.578 billion yuan, achieving a best return of 242.9% and a worst return of -26.25% during the tenure [3]